metastatic non-small cell lung cancer

Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer
Fierce Pharma
Thu, 10/12/23 - 11:34 am
Pfizer
Braftovi
Maktovi
metastatic non-small cell lung cancer
FDA
Gilead unveils promising data from trial of combo therapy for lung cancer
Clinical Trials Arena
Mon, 09/11/23 - 12:34 pm
Gilead Sciences
Trodelvy
metastatic non-small cell lung cancer
BioNTech's OncoC4 partnership off to good start with mid-stage trial results
Yahoo/Reuters
Fri, 06/2/23 - 10:27 am
BioNTech
OncoC4
clinical trials
lung cancer
gotistobart
metastatic non-small cell lung cancer
FDA Accepts SNDAs For Pfizer's Braftovi + Mektovi
NASDAQ
Wed, 04/5/23 - 10:18 am
Pfizer
FDA
Braftovi
Mektovi
metastatic non-small cell lung cancer
Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class
Fierce Biotech
Thu, 03/16/23 - 07:02 pm
Merck
Keytruda
clinical trials
vibostolimab
non-small cell lung cancer
metastatic non-small cell lung cancer
Exelixis drug fails PhIII lung cancer trial with Cabometyx and Tecentriq combo
Endpoints
Fri, 12/9/22 - 10:39 am
Exelixis
Cabometyx
Tecentriq
metastatic non-small cell lung cancer
clinical trials
Propel fails to propel Nektar
EP Vantage
Mon, 11/8/21 - 10:48 am
Nektar Therapeutics
Merck
bempegaldesleukin
clinical trials
metastatic non-small cell lung cancer
WCLC: AstraZeneca's detailed Imfinzi, tremelimumab data in metastatic NSCLC are far from a clear-cut win
Fierce Pharma
Fri, 09/10/21 - 11:05 am
WCLC
AstraZeneca
tremelimumab
metastatic non-small cell lung cancer
Iovance (IOVA) Announces Lung Cancer Study Data on TIL Therapy
Yahoo/Zacks.com
Wed, 06/30/21 - 10:52 am
Iovance
LN-145
metastatic non-small cell lung cancer
Novartis’ Autoimmune Drug Not Up for the Challenge in Phase III Cancer Trial
BioSpace
Tue, 03/9/21 - 09:47 pm
Novartis
canakinumab
clinical trials
metastatic non-small cell lung cancer
Setback for Novartis drug in advanced lung cancer trial
Biopharma Reporter
Tue, 03/9/21 - 10:40 am
Novartis
clinical trials
canakinumab
metastatic non-small cell lung cancer
FDA Approves Merck KGaA's Tepmetko for Aggressive Lung Cancer
BioSpace
Wed, 02/3/21 - 11:04 pm
Merck KGaA
Tepmetko
FDA
metastatic non-small cell lung cancer
In a first, Janssen submits lung cancer bispecific hopeful amivantamab to the FDA
Fierce Biotech
Thu, 12/3/20 - 10:55 am
Janssen
non-small cell lung cancer
FDA
amivantamab
JNJ
metastatic non-small cell lung cancer
BeiGene beefs up PD-1 data with positive PhIII results for tislelizumab, this time in metastatic NSCLC
Endpoints
Tue, 11/17/20 - 11:00 am
BeiGene
metastatic non-small cell lung cancer
FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC
Pharmaceutical Business Review
Wed, 05/27/20 - 10:30 am
Bristol-Myers Squibb
Opdvio
Yervoy
metastatic non-small cell lung cancer
FDA approves Genentech’s Tecentriq as first-line monotherapy for certain people with metastatic NSCLC
Pharmaceutical Business Review
Tue, 05/19/20 - 10:44 am
Genentech
Roche
Tecentriq
FDA
metastatic non-small cell lung cancer
Roche’s TIGIT drug shows promise in untreated lung cancer
Pharmaforum
Fri, 05/15/20 - 10:56 am
Roche
ASCO 2020
tiragolumab
Tecentriq
metastatic non-small cell lung cancer
Takeda gets FDA breakthrough therapy status for mobocertinib to treat certain type of lung cancer
Pharmaceutical Business Review
Tue, 04/28/20 - 11:45 pm
Takeda
FDA
mobocertinib
metastatic non-small cell lung cancer
J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation
BioSpace
Thu, 03/12/20 - 11:03 am
Janssen
JNJ
FDA
JNJ-6372
breakthrough therapy
metastatic non-small cell lung cancer
Janssen gets FDA breakthrough therapy status for JNJ-6372 to treat metastatic NSCLC
Pharmaceutical Business Review
Wed, 03/11/20 - 10:26 am
Janssen
JNJ
FDA
JNJ-6372
metastatic non-small cell lung cancer

Pages